Supplement Table 2: Characteristics of terminated trials

|  |  |  |  |
| --- | --- | --- | --- |
| Study characteristics (n) | Results posted or published (170) | Results not posted or published (139) | p-value |
| Completed after January 1st 2008 (%) | 155 (91.18) | 117 (84.17) | 0.06 |
| Type of study   1. Interventional 2. Observational / registry | 154 (90.59)  16 (9.41) | 107 (76.98)  32 (23.02) | <0.01 |
| Funding source   1. Industry 2. Other 3. Multiple sources | 68 (40)  65 (38.24)  37 (21.76) | 52 (37.41)  61 (43.88)  26 (18.71) | 0.58 |
| Phase   1. I 2. II 3. III 4. IV 5. Not reported/ not applicable | 8 (4.71)  39 (22.94)  54 (31.76)  15 (8.82)  54 (31.76) | 10 (7.19)  30 (21.58)  22 (15.83)  10 (7.19)  67 (48.20) | <0.01 |
| Endpoint   1. Clinical 2. Non-clinical | 163 (95.88)  7 (4.12) | 126 (90.65)  13 (9.35) | 0.06 |
| Intervention type   1. Biologic 2. Device 3. Drug 4. Procedure 5. Other | 25 (14.71)  23 (13.53)  84 (49.41)  17 (10.00)  21 (12.35) | 5 (3.60)  12 (8.63)  59 (42.45)  16 (11.51)  47 (33.81) | <0.0001 |
| No of centers   1. Single 2. Multiple 3. Not known | 79 (46.47)  89 (52.35)  2 (1.18) | 76 (54.68)  57 (41.01)  6 (4.32) | <0.05 |
| Trial duration in days (SD) | 990 (846.3) | 928.6 (757.1) | 0.51 |
| Reason for termination for terminated or suspended trials   1. Enrolment issues 2. Safety concern, adverse events 3. Medical futility or lack of efficacy 4. Issues related to funding, personnel, supplies, local or federal regulation 5. Unclear | 67 (39.41)  13 (7.65)  22 (12.94)  29 (17.06)  39 (22.94) | 71 (51.08)  2 (1.44)  12 (8.63)  26 (18.71)  28 (20.14) | 0.03 |

Legend: SD, Standard Deviation.